Overview
- A Lancet consensus led by Professor Helena Teede formally renamed Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome this week after a 14‑year global consultation involving 56 organisations and more than 14,000 respondents.
- The new label stresses that the disorder is driven by endocrine and metabolic dysfunction—not primarily ovarian cysts—and highlights insulin resistance and androgen excess as central mechanisms.
- Diagnostic rules for adults remain unchanged for now, requiring two of three features (irregular ovulation, hyperandrogenism, or polycystic ovaries/elevated AMH), but experts are urging routine metabolic checks such as fasting glucose, HbA1c and lipid screening.
- The condition affects roughly 170 million women worldwide and may be undiagnosed in up to 70 percent of cases; the reframing aims to reduce blame, shorten diagnostic delays and address mental‑health and quality‑of‑life impacts illustrated by personal accounts.
- A staged three‑year rollout will update guidelines, education and disease coding by about 2028, with particular attention to high metabolic risk groups such as South Asian women where clinicians say the change could prompt earlier diabetes prevention and culturally tailored care.